Advances in Treatment and Management of Immune Thrombocytopenia

Expert panelists review new data on the management of immune thrombocytopenia and consider how these data may impact clinical practice.

EP. 1: Making a Diagnosis of Immune Thrombocytopenia

June 30th 2022

Opening their discussion on immune thrombocytopenia (ITP), expert panelists review criteria for diagnosis and highlight differences between adult and pediatric populations.

EP. 2: Optimizing Frontline Therapy in ITP: Treatment Selection and Goals

June 30th 2022

Shared insight on treatment goals for immune thrombocytopenia and how physicians might optimally select frontline therapy.

EP. 3: The Significance of Patient Age in Treatment and Management of ITP

July 7th 2022

A commentary on the significance of the patient’s age in treating and managing ITP.

EP. 4: Defining Chronic or Persistent Immune Thrombocytopenia

July 7th 2022

Expert perspectives on how to identify chronic or persistent disease in patients diagnosed with immune thrombocytopenia.

EP. 5: What is the Role of Splenectomy in Chronic Immune Thrombocytopenia?

July 14th 2022

Panelists consider when they would select splenectomy over second-line systemic therapy in patients with immune thrombocytopenia.

EP. 6: Use of Rituximab Therapy in Chronic Immune Thrombocytopenia

July 14th 2022

Focusing on second-line systemic agents in immune thrombocytopenia, experts review the historical use of rituximab therapy.

EP. 7: Chronic Immune Thrombocytopenia: Considerations for Fostamatinib Therapy

July 21st 2022

Expert perspectives on the selection and use of fostamatinib as second-line therapy in patients with immune thrombocytopenia.

EP. 8: Thrombopoietin Receptor Agonists in Pediatric Immune Thrombocytopenia

July 21st 2022

Shared insight on thrombopoietin receptor agonist (TPO-RA) use in the pediatric setting of immune thrombocytopenia management.

EP. 9: Selecting an Oral TPO-RA for Chronic Immune Thrombocytopenia

July 28th 2022

A brief discussion of factors that influence selection of oral versus injectable TPO-RA therapy for ITP.

EP. 10: Eltrombopag in Chronic Immune Thrombocytopenia

July 28th 2022

Expert panelists consider clinical trial data on and personal experience with using eltrombopag, an oral TPO-RA, in immune thrombocytopenia.

EP. 11: Data on Avatrombopag in Chronic ITP

August 4th 2022

A commentary on clinical experience with avatrombopag, another oral TPO-RA, in treating ITP.

EP. 12: Use of Romiplostim in Chronic Immune Thrombocytopenia

August 4th 2022

Considerations for the uptake and use of romiplostim, an injectable thrombopoietin receptor agonist, in immune thrombocytopenia.

EP. 13: Risk of Thrombosis With TPO-RAs in Immune Thrombocytopenia

August 11th 2022

Comprehensive discussion on nuancing the risk of thrombosis with thrombopoietin receptor agonists in immune thrombocytopenia.

EP. 14: How Does Treatment Duration Impact Outcomes in ITP?

August 11th 2022

Experts consider how treatment duration can impact patient outcomes in immune thrombocytopenia and discuss discontinuation of TPO-Ras.

EP. 15: Treating Patients With Immune Thrombocytopenia in the Era of COVID-19

August 18th 2022

A brief review of how the management of patients with immune thrombocytopenia has been impacted by the COVID-19 pandemic.

EP. 16: Novel Treatment Strategies in Immune Thrombocytopenia: Frontline Use of TPO-RAs

August 18th 2022

Shared insight on clinical trials investigating the frontline use of thrombopoietin receptor agonists in patients with immune thrombocytopenia.

EP. 17: Novel Treatment Strategies in Immune Thrombocytopenia: Complement Inhibitors

August 25th 2022

Panelists review data behind sutimlimab, a complement inhibitor being investigated in the setting of immune thrombocytopenia.

EP. 18: Other Novel Therapeutic Agents in Immune Thrombocytopenia

August 25th 2022

Before closing out their discussion on novel treatment approaches in ITP, experts review data behind FcR-, BTK-, and CD38-targeted therapies.

EP. 19: Future Directions in the Management of Immune Thrombocytopenia

September 1st 2022

Expert panelists reflect on the advent of newer therapies in immune thrombocytopenia and look toward future evolutions in care.